Tilray Brands, Inc. (NASDAQ:TLRY - Get Free Report) Director David Hopkinson sold 33,556 shares of the business's stock in a transaction on Tuesday, April 21st. The stock was sold at an average price of $6.94, for a total value of $232,878.64. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Tilray Brands Stock Up 14.2%
TLRY opened at $7.87 on Thursday. Tilray Brands, Inc. has a one year low of $3.51 and a one year high of $23.20. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.66 and a current ratio of 2.79. The stock's fifty day moving average is $7.04 and its 200-day moving average is $9.53. The company has a market capitalization of $917.24 million, a PE ratio of -0.58 and a beta of 2.00.
Tilray Brands (NASDAQ:TLRY - Get Free Report) last posted its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.10). Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.The firm had revenue of $206.73 million during the quarter, compared to the consensus estimate of $201.35 million. During the same period in the prior year, the firm posted ($0.87) EPS. On average, equities analysts predict that Tilray Brands, Inc. will post -0.55 EPS for the current fiscal year.
Wall Street Analyst Weigh In
TLRY has been the topic of a number of research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Tilray Brands in a research note on Wednesday, January 21st. TD Cowen dropped their price objective on Tilray Brands from $10.00 to $7.00 and set a "buy" rating on the stock in a research note on Monday, March 30th. Zacks Research raised Tilray Brands from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 11th. Roth Mkm raised Tilray Brands from a "neutral" rating to a "buy" rating and set a $10.00 price objective on the stock in a research note on Thursday, April 2nd. Finally, Canaccord Genuity Group initiated coverage on Tilray Brands in a research note on Tuesday, January 27th. They issued a "hold" rating on the stock. Three research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $11.50.
View Our Latest Report on TLRY
Tilray Brands News Summary
Here are the key news stories impacting Tilray Brands this week:
- Positive Sentiment: Reports the U.S. Justice Department will loosen cannabis restrictions sparked a sector-wide rally that lifted Tilray shares as investors price in a regulatory catalyst that would expand U.S. market opportunity and margin potential. Curaleaf and More Cannabis Stocks Soar. A Regulatory Breakthrough Is Coming.
- Positive Sentiment: Political momentum also surfaced after reports that former President Trump urged rapid reclassification of cannabis, reinforcing the regulatory narrative and prompting short-term buying and bullish options positioning. Tilray Stock Pops on New Trump-Driven Cannabis Hopes. Should You Chase the Rally?
- Positive Sentiment: Technical and research commentary points to a recovery setup: market write-ups highlight an early breakout and momentum that could carry TLRY higher if regulatory progress continues. Tilray Brands (TLRY) Price Forecast: Cannabis Rescheduling Fuels Recovery
- Positive Sentiment: Unusually large options activity: ~45,077 call contracts were bought (about +89% vs. typical daily call volume), indicating speculative bullish bets that can amplify upside moves in the underlying stock.
- Positive Sentiment: Analyst optimism: Roth Capital published a bullish note suggesting Tilray could rally >40% over 12 months based on improving fundamentals and the regulatory outlook, which can attract momentum and retail interest. 1 Wall Street Analyst Says Tilray Stock Could Jump Over 40%. Should You Believe It?
- Neutral Sentiment: Trading was briefly halted on a LULD (Limit Up/Limit Down) pause around 11:49 AM — a mechanical volatility control that indicates rapid price movement but doesn’t change the underlying drivers. (No external link provided.)
- Negative Sentiment: Insider selling: Director David G. Hopkinson sold 33,556 shares at an average $6.94 on April 21. Insider sales can be interpreted by some investors as a cautionary signal, even though they may be routine or pre-planned. Form 4 — David G. Hopkinson Sale
Institutional Investors Weigh In On Tilray Brands
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Apollon Wealth Management LLC acquired a new stake in shares of Tilray Brands during the first quarter worth $96,000. Pictet Asset Management Holding SA raised its position in shares of Tilray Brands by 38.9% during the first quarter. Pictet Asset Management Holding SA now owns 18,387 shares of the company's stock worth $119,000 after purchasing an additional 5,145 shares during the period. Alpine Global Management LLC acquired a new stake in shares of Tilray Brands during the fourth quarter worth $169,000. Voloridge Investment Management LLC acquired a new stake in shares of Tilray Brands during the fourth quarter worth $824,000. Finally, Polymer Capital Management US LLC acquired a new stake in shares of Tilray Brands during the fourth quarter worth $1,058,000. 9.35% of the stock is owned by institutional investors and hedge funds.
Tilray Brands Company Profile
(
Get Free Report)
Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.
Tilray's product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
